<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/abt-20221231.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000162828023004026/0001628280-23-004026-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Abbott Laboratories

Abbott Laboratories: COVID-19 Impact on Financial Performance
Current Analysis:
Abbott Laboratories has had a successful few years, despite the COVID-19 pandemic. Despite the pandemic, Abbott has managed to increase total sales since 2020 due to the introduction of new products across various businesses, as well as higher sales of existing products. Sales in emerging markets increased 5.6 percent in 2022 and 19.6 percent in 2021, excluding the impact of foreign exchange. In the US, Abbott’s sales increased 8.8 percent in 2022 and 3.5 percent in 2021, excluding the impact of foreign exchange. Abbott’s COVID-19 testing-related sales totaled approximately $8.4 billion in 2022, $7.7 billion in 2021, and $3.9 billion in 2020.

Forward-Looking Analysis:
Abbott is continually monitoring the effects of the pandemic on its operations and is taking aggressive steps to limit exposure to COVID-19 and enhance the safety of facilities for its employees. On January 30, 2023, the U.S. government announced that it plans to end the COVID-19 public health emergency on May 11, 2023. Abbott is evaluating the potential impacts of the end of the public health emergency, and it will continue to monitor further regulatory actions from relevant U.S. government agencies and assess potential impacts on pandemic-related government policies and product authorizations. Abbott expects the COVID-19 pandemic to shift to an endemic state in 2023, which would likely result in significantly lower demand for COVID-19 tests. Despite the uncertainly of the pandemic, Abbott has been able to maintain a successful financial performance and is well-positioned for future growth.

Announcement: ABT 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000110465923023291/tm236955d1_8k.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000110465923023291/0001104659-23-023291-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 5.03 Item 9.01

Announcement: ABT 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000110465923015184/tv0146-abbottlaboratories.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000110465923015184/0001104659-23-015184-index.htm>Original filing index</a>
                    </div>

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ABT SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000130655023007894/us0028241000_020623.txt>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1800/000130655023007894/0001306550-23-007894-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/abt-20230125.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm>Original filing index</a>
                        </div>

Form 8-K - Current report - Item 2.02 Item 9.01

Analyst Summary: Abbott reported fourth-quarter sales of $10.1 billion, down 12% YoY, but grew 5.4% on an organic basis, excluding COVID-19 testing-related sales. Full-year 2022 sales increased 1.9% on a reported basis and 7.4% on an organic basis, excluding COVID-19 testing-related sales and U.S. infant formula sales that were impacted by manufacturing disruptions. According to Robert B. Ford, Chairman and CEO of Abbott, their vector delivering COVID-19 vaccine showed promising preclinical results, which they plan to test in human clinical trials next year. Abbott's Medical Devices portfolio saw the launch of several new products, including Abbott's latest generation transcatheter aortic valve implantation system and the rechargeable spinal cord stimulator that treats chronic pain, allowing continuous glucose monitoring system to be named the "Best Medical Technology" of the last 50 years. Abbott declared a cash dividend and continues to strengthen its products with promising new product launches that position them well for the future. However, the unpredictability of foreign exchange rates could significantly impact reported sales growth.

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1800/000110465922125832/tm2232123d1_8k.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1800/000110465922125832/0001104659-22-125832-index.htm>Original filing index</a>
                        </div>